The sale of a large fertilizer plant in southeast Iowa will no longer go through after two fertilizer companies called off an $8 billion deal.
CF Industries and OCI N.V. announced Monday they are canceling their deal, which involved Illinois-based CF Industries purchasing the North American and European operations of Netherlands-based OCI.
The buy would have included CF Industries taking over ownership of OCI’s $2 billion fertilizer plant in Wever, which is currently under construction and operates as Iowa Fertilizer Co.
The two companies said “changes in the regulatory and commercial environments” caused them to terminate the deal, specifically mentioning new tax regulations issued by the U.S. Treasury Department.
Last month, the Treasury Department and Internal Revenue Service announced new rules intended to curb “inversions,” The New York Times reported. Corporate inversions are the practice of companies re-incorporating in a foreign country, such as through a merger, often to lower their tax bills. In the proposed CF-OCI deal, CF Industries would have become a subsidiary of a new company headquartered in the Netherlands.
Full Content: The Des Moines Register
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas